
Three medical marijuana companies are suing the DEA in federal court over the restrictions it imposed for rescheduling protections. Our đ„-TAKE: Medical cannabis companies are now litigating to lock in the real-world benefits of Schedule III, proving the industry has both the legal firepower and the economic incentive to stop the DEA from quietly gutting rescheduling gains through last-minute supply-chain rules that ignore how closed state markets actually function.
đ€ ANALYSIS: Three state-licensed medical marijuana operatorsâStandard Wellness Utah, Verde Americano (Arizona), and NW Confections OK (Oklahoma)âfiled a petition for review on November 18, 2026, in the U.S. Court of Appeals for the D.C. Circuit challenging DEA guidance issued on October 30. That guidance, titled âDEA Medical Marijuana Timely Applicant Information,â requires businesses that filed complete DEA registration applications between April 28 and June 26, 2026 (âtimely applicantsâ) to restructure their supply chains so that, by November 29, they only buy from and sell to other timely applicants or already-registered entities. Failure to do so could jeopardize applications or registrations.â
This follows the Trump administrationâs April 2026 order (issued by Acting Attorney General Todd Blanche) that moved qualifying state-licensed medical marijuana activities and certain FDA-approved cannabis products from Schedule I to Schedule III. The order and accompanying regulations allowed timely applicants to continue operating under their state licenses while DEA processed applications. DEA has already issued federal registrations to more than 900 medical dispensaries (primarily in medical-only states such as Alabama, Florida, Mississippi, South Dakota, Texas, Virginia, and West Virginia) and published a list of roughly 7,000 timely-applicant locations. At the same time, DEA has issued orders to show cause rejecting applications in several dual-use or adult-use states (including California, Illinois, Minnesota, Oregon, and others), citing closed-system and treaty concerns.â
The companies argue the November 29 deadline is unlawful on three grounds. First, it contradicts the rescheduling order and the regulation (21 C.F.R. § 1301.13(k)(7)), which permit timely applicants to operate under state licenses for the duration of the pending application without conditioning that authority on the registration status of their trading partners or imposing a hard calendar cutoff. Second, the guidance functions as a legislative rule imposing new substantive obligations (partner verification and forced supply-chain restructuring, on pain of denial or revocation) that was issued without notice-and-comment rulemaking. Third, it is arbitrary and capricious because DEA acknowledged the need for adjustments but gave only 30 days, failed to consider the reliance interests of operators who built businesses under state regimes, and ignored the concrete costs of severing relationships in markets that prohibit interstate commerce.â
The petition details immediate harm: Standard Wellness Utah faces the loss of roughly $275,900 in monthly sales and suppliers for about 16% of its oil; Verde expects to cut 70% of its workforce; NW Confections projects its Oklahoma operations will become insolvent. Markets have already reactedâpartners are quarantining product, demanding proof of DEA status, and pausing orders. The companies had asked DEA to suspend the deadline and received no response; they seek a court stay or ruling before November 25.â
This dispute sits inside a larger, still-unsettled federal landscape. Separate consolidated litigation in the same D.C. Circuit (brought by groups including Smart Approaches to Marijuana, a drug-testing association, and the biopharma firm MMJ International Holdings) is challenging the underlying rescheduling order itself; a request to stay the order was denied, so Schedule III remains in effect pending merits review. State regulators have also complained of abrupt disruption and poor communication from DEA. Adult-use cannabis remains Schedule I, and the medical rescheduling path does not automatically open interstate commerce or fully resolve 280E, banking, or other issues for every operator.
For the industry, the lawsuit is a high-signal development. Operators are treating the Schedule III framework as sufficiently valuable (tax relief, clearer federal status, banking and capital-market access) that they will spend legal resources to defend workable implementation rather than absorb arbitrary restrictions. A stay or favorable ruling could preserve existing supply chains, reduce near-term insolvency risk in thinner medical markets, and pressure DEA toward rules that better account for state-level closed systems. It also underscores the practical limits of the current approach: without enough timely registrants in a given state, the closed-loop requirement can fracture viable markets and undermine patient access. Conversely, if the court upholds the guidance, many operators face rapid, costly reconfiguration or loss of federal protections.
The case is in its earliest stage. The requested near-term stay will be the first practical test of whether courts will intervene in the rollout details. Broader rescheduling challenges remain pending, and DEAâs selective approach to dual-use states continues to create a patchwork. Overall, the filing shows medical operators are no longer passive recipients of federal reformâthey are actively shaping how (and whether) the benefits of Schedule III are realized on the ground.

